Detail Information of Genetic Polymorphisms
| General Information of Drug Transporter (DT) | |||||
|---|---|---|---|---|---|
| DT ID | DTD0001 Transporter Info | ||||
| Gene Name | ABCC1 | ||||
| Protein Name | Multidrug resistance-associated protein 1 | ||||
| Gene ID | |||||
| UniProt ID | |||||
| Genetic Polymorphisms of DT (GPD) | |||||
| Genetic Polymorphism | rs119774 | ||||
| Site of GPD | chr16:15992976 (GRCh38.p12) | ||||
| GPD Type | SNP | ||||
| Allele(s) in dbSNP | C>T | ||||
| Minor Allele Frequency | T=0.0391/196 (Global) | ||||
| Genotype CT | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Montelukast | Drug Info | Asthma | Correlated with the increased changes in FEV1 in patients (compare with genotype CC) | [ 1] | |
| Genetic Polymorphism | rs4148350 | ||||
| Site of GPD | chr16:16076620 (GRCh38.p12) | ||||
| GPD Type | SNP | ||||
| Allele(s) in dbSNP | G>T | ||||
| Minor Allele Frequency | T=0.0681/341 (Global) | ||||
| Allele T | Click to Show/Hide the Full List of Affected Drugs: 3 Drugs in Total | ||||
| Daunorubicin | Drug Info | Neoplasm | Irrelevant to the likelihood of cardiotoxicity in patients (compare with allele G) | [ 2] | |
| Doxorubicin | Drug Info | Neoplasm | Irrelevant to the likelihood of cardiotoxicity in patients (compare with allele G) | [ 2] | |
| Anthracyclines | N.A. | Neoplasm | Correlated with the increased likelihood of cardiotoxicity in patients (compare with allele G) | [ 3] | |
| Genetic Polymorphism | rs45511401 | ||||
| Site of GPD | chr16:16079375 (GRCh38.p12) | ||||
| GPD Type | SNP | ||||
| Allele(s) in dbSNP | G>T | ||||
| Minor Allele Frequency | T=0.0154/77 (Global) | ||||
| Allele T | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Doxorubicin | Drug Info | Non-Hodgkin Lymphoma | Correlated with the increased cardiotoxicity risk in patients (compare with allele G) | [ 4] | |
| Genetic Polymorphism | rs35592 | ||||
| Site of GPD | chr16:16047966 (GRCh38.p12) | ||||
| GPD Type | SNP | ||||
| Allele(s) in dbSNP | T>C | ||||
| Minor Allele Frequency | C=0.3704/1855 (Global) | ||||
| Allele C | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Methotrexate | Drug Info | Rheumatoid Arthritis | Irrelevant to the drug response in patients (compare with Allele T) | [ 5] | |
| Genotype TT | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Methotrexate | Drug Info | Psoriasis | Correlated with the increased drug response in patients (compare with genotypes CC + CT) | [ 6] | |
| Genetic Polymorphism | rs17501331 | ||||
| Site of GPD | chr16:15995584 (GRCh38.p12) | ||||
| GPD Type | SNP | ||||
| Allele(s) in dbSNP | A>G | ||||
| Minor Allele Frequency | G=0.0383/192 (Global) | ||||
| Genotypes AG + GG | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Irinotecan | Drug Info | Colorectal Neoplasm | Correlated with the decreased severity of neutropenia in patients (compare with genotype AA) | [ 7] | |
| Genetic Polymorphism | rs212091 | ||||
| Site of GPD | chr16:16142793 (GRCh38.p12) | ||||
| GPD Type | SNP | ||||
| Allele(s) in dbSNP | T>A / T>C | ||||
| Minor Allele Frequency | C=0.1360/681 (Global) | ||||
| Genotypes CC + CT | Click to Show/Hide the Full List of Affected Drugs: 4 Drugs in Total | ||||
| Lamivudine | Drug Info | HIV Infection | Correlated with the increased drug resistance in patients (compare with Genotype TT) | [ 8] | |
| Lopinavir | Drug Info | HIV Infection | Correlated with the increased drug resistance in patients (compare with Genotype TT) | [ 8] | |
| Zidovudine | Drug Info | HIV Infection | Correlated with the increased drug resistance in patients (compare with Genotype TT) | [ 8] | |
| Ritonavir | Drug Info | HIV Infection | Correlated with the increased drug resistance in patients (compare with Genotype TT) | [ 8] | |
| Genetic Polymorphism | rs2238476 | ||||
| Site of GPD | chr16:16120015 (GRCh38.p12) | ||||
| GPD Type | SNP | ||||
| Allele(s) in dbSNP | G>A | ||||
| Minor Allele Frequency | A=0.0691/346 (Global) | ||||
| Genotype GG | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Methotrexate | Drug Info | Psoriasis | Correlated with the increased drug response in patients (compare with allele A); Correlated with the increased toxicity risk in patients (compare with genotypes AA + AG) | [ 6] | |
| Genetic Polymorphism | rs246240 | ||||
| Site of GPD | chr16:16025167 (GRCh38.p12) | ||||
| GPD Type | SNP | ||||
| Allele(s) in dbSNP | A>G | ||||
| Minor Allele Frequency | G=0.1827/915 (Global) | ||||
| Genotypes AG + GG | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Methotrexate | Drug Info | Rheumatoid Arthritis | Correlated with the decreased drug response in patients (compare with genotype AA) | [ 9] | |
| Genotypes GG + AG | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Methotrexate | Drug Info | Psoriasis | Correlated with the decreased onset of toxicity risk in patients (compare with genotype AA) | [ 6] | |
| Genetic Polymorphism | rs28364006 | ||||
| Site of GPD | chr16:16134392 (GRCh38.p12) | ||||
| GPD Type | SNP | ||||
| Allele(s) in dbSNP | A>G | ||||
| Genotype GG | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Methotrexate | Drug Info | Psoriasis | Correlated with the increased drug response in patients (compare with allele AG) | [ 6] | |
| Genetic Polymorphism | rs35621 | ||||
| Site of GPD | chr16:16074751 (GRCh38.p12) | ||||
| GPD Type | SNP | ||||
| Allele(s) in dbSNP | C>T | ||||
| Minor Allele Frequency | T=0.1248/625 (Global) | ||||
| Genotypes CT + TT | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Sn-38 | Drug Info | Colorectal Neoplasm | Correlated with the increased drug exposure in patients (compare with genotype CC) | [ 7] | |
| Genetic Polymorphism | rs3743527 | ||||
| Site of GPD | chr16:16141824 (GRCh38.p12) | ||||
| GPD Type | SNP | ||||
| Allele(s) in dbSNP | C>T | ||||
| Minor Allele Frequency | T=0.2943/1474 (Global) | ||||
| Genotypes CT + TT | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Irinotecan | Drug Info | Colorectal Neoplasm | Correlated with the decreased severity of neutropenia in patients (compare with genotype CC) | [ 7] | |
| Genetic Polymorphism | rs3784864 | ||||
| Site of GPD | chr16:16031468 (GRCh38.p12) | ||||
| GPD Type | SNP | ||||
| Allele(s) in dbSNP | G>A | ||||
| Minor Allele Frequency | A=0.3271/1638 (Global) | ||||
| Genotypes AG + GG | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Methotrexate | Drug Info | Rheumatoid Arthritis | Correlated with the decreased drug response in patients (compare with genotype AA) | [ 9] | |
| Genetic Polymorphism | rs6498588 | ||||
| Site of GPD | chr16:15938949 (GRCh38.p12) | ||||
| GPD Type | SNP | ||||
| Allele(s) in dbSNP | A>T | ||||
| Minor Allele Frequency | A=0.3770/1888 (Global) | ||||
| Genotypes AT + TT | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Sn-38 | Drug Info | Colorectal Neoplasm | Correlated with the increased drug exposure in patients (compare with genotype AA) | [ 7] | |
| References | |||||
| 1 | Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am J Respir Crit Care Med. 2006 Feb 15;173(4):379-85. | ||||
| 2 | Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Pediatr Blood Cancer. 2013 Aug;60(8):1375-81. | ||||
| 3 | Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol. 2012 May 1;30(13):1422-8. | ||||
| 4 | NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation. 2005 Dec 13;112(24):3754-62. | ||||
| 5 | Replication study of polymorphisms associated with response to methotrexate in patients with rheumatoid arthritis. Sci Rep. 2018 May 9;8(1):7342. | ||||
| 6 | Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis. J Invest Dermatol. 2008 Aug;128(8):1925-9. | ||||
| 7 | ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia. Pharmacogenomics J. 2018 Jan;18(1):35-42. | ||||
| 8 | ABCB1 and ABCC1 variants associated with virological failure of first-line protease inhibitors antiretroviral regimens in Northeast Brazil patients. J Clin Pharmacol. 2013 Dec;53(12):1286-93. | ||||
| 9 | Pharmacogenomics of Methotrexate Membrane Transport Pathway: Can Clinical Response to Methotrexate in Rheumatoid Arthritis Be Predicted? Int J Mol Sci. 2015 Jun 16;16(6):13760-80. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.